Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDYZE5)

Drug Name

PMID19954973C4 Drug Info

Synonyms

GTPL8623; BDBM50305346

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Investigative Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Carboxypeptidase B1 (CPB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US8710232, 8	DM1MQ7J	N. A.	N. A.	Patented	[2]
US8710232, 1	DMCNAM9	N. A.	N. A.	Patented	[2]
US8710232, 7	DMCNS9T	N. A.	N. A.	Patented	[2]
PMID14640538C3	DMR2L6X	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting Carboxypeptidase B2 (CPB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR-126119	DMKHM7O	Cerebrovascular ischaemia	8B1Z	Phase 1	[4]
UK-396082	DMFYKDX	Thrombosis	DB61-GB90	Phase 1	[1]
DS-1040	DMXCN37	Ischemic stroke	8B11.5Z	Phase 1	[5]
SAR-104772	DMQ9ZY0	Cerebrovascular ischaemia	8B1Z	Phase 1	[6]
AZD-9684	DMHA5ME	Thrombosis	DB61-GB90	Discontinued in Phase 2	[7]
PMID14640538C3	DMR2L6X	Discovery agent	N.A.	Investigative	[3]
DL-benzylsuccinic acid	DMHI9ZJ	Discovery agent	N.A.	Investigative	[8]
3-mercapto-2-(piperidin-3-yl)propanoic acid	DMPJBNC	Discovery agent	N.A.	Investigative	[9]
6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid	DMMUE05	Discovery agent	N.A.	Investigative	[10]
3-mercapto-2-(piperidin-4-yl)propanoic acid	DMYQG7A	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
2	Imidazole derivatives used as TAFIa inhibitors. US8710232.
3	Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
4	TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
5	Clinical pipeline report, company report or official report of Daiichi Sankyo.
6	Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
7	Clinical pipeline report, company report or official report of AstraZeneca.
8	A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
9	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
10	Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.